- Abstract 3022832: Discovery and Preclinical Characterization of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Abstract3021589: Efficacy of RGLS4326 in Human Primary ADPKD 3D-Cyst Cultured Cells.
- Abstract3021851: RGLS4326 Confers Efficacy and Modulate Aberrant Signaling and Metabolic Pathways in PKD Mouse Models.
"We are pleased to be making several presentations on our RGLS4326 program during this year's Kidney Week meeting that we believe further demonstrate the compound's novel mechanism and therapeutic potential to treat patients with ADPKD," said Jay Hagan, President and Chief Executive Officer of Regulus.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain goals and objectives (including with respect to the development and therapeutic potential of its RGLS4326 program in ADPKD). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus filings with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/regulus-to-present-preclinical-data-supporting-rgls4326-as-a-novel-therapeutic-in-development-for-autosomal-dominant-polycystic-kidney-disease-at-asns-kidney-week-2018-300735419.html
Investor Relations Contact: Dan Chevallard, Chief Financial Officer, 858-202-6376, firstname.lastname@example.org